Trigemina Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

La Jolla, Calif. May 7, 2015 — Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. Charles Yeomans, president and chief executive officer of Trigemina, will participate in a panel on May 11th titled Groundbreaking Discoveries and Innovations in Diseases of the Central Nervous System and Neurological Diseases.

The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of leading family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by the community of La Jolla, California including The University of California, San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Trigemina’s research and scientific insights in the safe delivery of effective, non-opioid pain therapy positions them to make major contributions to the treatment of pain with an initial focus on migraine and other debilitating types of head pain.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to the treatment of migraine and other types of pain afflicting a vast number of people around the world today,” said Mr. Yeomans. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About Trigemina
Trigemina is a privately owned, clinical stage company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina’s lead product candidate, TI-114, is a patented new drug candidate that includes oxytocin. TI-114 has shown promising results for use as a safe and effective therapy for most forms of chronic or subacute head pain. Further information is available on the Company’s website: www.trigemina.com.

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

For more information: http://cavendishglobal.com

For Further Information Contact:

For Trigemina
Charles Yeomans
President and CEO, Trigemina
925-377-0664

Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org

For Cavendish:
Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435

Comments are closed.